Fig. 3From: The amount of DNA combined with TP53 mutations in liquid biopsy is associated with clinical outcome of renal cancer patients treated with immunotherapy and VEGFR-TKIsStratification of patients into short (blue column), intermediate (grey column) and long (orange column) responders, according to the cfDNA cut-points (A). Median PFS of short (blue line), intermediate (grey line) and long (orange line) responders, according to the cfDNA cut-points (B)Back to article page